ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

denifanstat

Also written as “Denifanstat”, “ASC40” and “TVB-2640”.

Its studies are mostly in Non-alcoholic Fatty Liver Disease · Acne Vulgaris · Glioblastoma · Neoplasms, led by 2 companies.

Drug pageTVB-2640: every studyAll 19 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 10, 202415 company-led studies, 2 open or runningNext primary completion: Aug 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sagimet Biosciencesits history only91 open or runningphase 3since Sep 10, 2024Aug 18, 2014Aug 2027phase 3 · NCT07863193
Ascletis Pharma61 open or runningphase 3since Oct 26, 2021Apr 14, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Ascletis Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Apr 14, 2020First study: phase 1 study in HealthyFirst studyNCT04352361 · 34 enrolled · China
  2. Apr 9, 2021Phase 1 study in HealthyNCT04843449 · 24 enrolled · China
  3. Jul 28, 2021Named denifanstatINNProposed as its International Nonproprietary Name in WHO's List 125 · before, TVB-2640
  4. Oct 26, 2021Phase 3 study in GlioblastomaNCT05118776 · 136 enrolled · China
  5. Oct 26, 2021Phase 2 study in Acne VulgarisNCT05104125 · 180 enrolled · China
  6. Dec 14, 2023Phase 3 study in Acne VulgarisNCT06192264 · 480 enrolled · China
  7. Jan 31, 2024Phase 3 study in Acne VulgarisNCT06248008 · 240 enrolled · China

TargetBeta

FASN →read by rule
“An orally bioavailable fatty acid synthase (FASN) inhibitor, ”NCIt, by rule

Studies

All 6 Ascletis Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06248008Acne Vulgaris · China3CompletedNov 12, 2025240
NCT06192264Acne Vulgaris · China3CompletedMay 19, 2025480
NCT05118776Glioblastoma · China3Active, not recruitingJun 2025136
NCT05104125Acne Vulgaris · China2CompletedApr 10, 2023180
NCT04843449Healthy · China1CompletedMay 6, 202124
NCT04352361Healthy · China1CompletedApr 29, 202034

How it is read

Names in the registry

  • “Denifanstat”, 3 entries
  • “ASC40”, 3 entries
  • “TVB-2640”, 3 entries
  • “ASC40 25mg”, 1 entry
  • “ASC40 50mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.